Batista RL, et al. - In this randomized, parallel, open-label clinical trial, authors assessed 59 candidates in the study group and 57 in the control group to find the clinical potency of the dopaminergic agonist cabergoline for residual nonfunctioning pituitary adenomas (NFPAs) following transsphenoidal surgery. They observed residual tumor shrinkage, stabilization, and enlargement in 28.8%, 66.1%, and 5.1% of cases, in the study group and in 10.5%, 73.7%, and 15.8% of those in the control group, respectively. The progression-free survival rate was 23.2 and 20.8 months for the study and control groups, respectively. They did not find any relation between tumor dopamine D2 receptor (D2R) and cabergoline responsiveness. Cabergoline was considered an effective drug without any significant side effects.